TScan Therapeutics (NASDAQ:TCRX) Receives “Outperform” Rating from Wedbush

TScan Therapeutics (NASDAQ:TCRX)‘s stock had its “outperform” rating reiterated by stock analysts at Wedbush in a research report issued on Tuesday,Benzinga reports. They currently have a $5.00 price target on the stock. Wedbush’s price target suggests a potential upside of 477.97% from the company’s previous close.

Several other research analysts also recently weighed in on TCRX. Needham & Company LLC restated a “buy” rating and set a $6.00 price objective on shares of TScan Therapeutics in a report on Tuesday. Wall Street Zen cut shares of TScan Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, May 9th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of TScan Therapeutics in a report on Tuesday, April 21st. Three investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $6.00.

TScan Therapeutics Trading Down 6.0%

Shares of TScan Therapeutics stock opened at $0.87 on Tuesday. The company has a debt-to-equity ratio of 0.34, a quick ratio of 6.65 and a current ratio of 6.65. TScan Therapeutics has a 52 week low of $0.85 and a 52 week high of $2.57. The stock has a 50 day moving average price of $1.08 and a two-hundred day moving average price of $1.06. The stock has a market capitalization of $56.53 million, a PE ratio of -0.90 and a beta of 1.03.

TScan Therapeutics (NASDAQ:TCRX) last issued its earnings results on Wednesday, May 6th. The company reported ($0.22) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.22). TScan Therapeutics had a negative return on equity of 91.94% and a negative net margin of 1,360.61%.The company had revenue of $0.98 million for the quarter, compared to analyst estimates of $2.50 million. As a group, equities analysts anticipate that TScan Therapeutics will post -1.11 earnings per share for the current fiscal year.

Institutional Trading of TScan Therapeutics

Several institutional investors have recently made changes to their positions in the company. Goldman Sachs Group Inc. lifted its position in shares of TScan Therapeutics by 6.0% during the first quarter. Goldman Sachs Group Inc. now owns 170,349 shares of the company’s stock valued at $235,000 after purchasing an additional 9,676 shares in the last quarter. JPMorgan Chase & Co. increased its stake in TScan Therapeutics by 8.5% in the 2nd quarter. JPMorgan Chase & Co. now owns 287,743 shares of the company’s stock valued at $417,000 after buying an additional 22,642 shares during the last quarter. Marshall Wace LLP purchased a new stake in TScan Therapeutics in the 2nd quarter valued at about $78,000. Qube Research & Technologies Ltd bought a new position in shares of TScan Therapeutics during the 2nd quarter worth approximately $99,000. Finally, Jane Street Group LLC bought a new position in shares of TScan Therapeutics during the 2nd quarter worth approximately $309,000. Institutional investors own 82.83% of the company’s stock.

About TScan Therapeutics

TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan’s approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.

The company’s pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors.